Tag: Altaris

New company unveiled at the annual ISCT conference in New Orleans combines two tenured and innovative CDMOs with a testing powerhouse

PHILADELPHIA — May 7, 2025 — Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies™, a global cell therapy CDMO and testing partner.  The company is headquartered in Philadelphia, Pennsylvania.

With modern facilities approved for commercial production in the United States (Allendale, NJ and Philadelphia), Europe (Munich) and Asia-Pacific (Yokohama, Japan), Minaris Advanced Therapies manufactures clinical-stage and commercial products on three continents and has a proven track record of delivering more than 7,500 GMP batches.

The company currently manufactures two commercial cell therapies and provides testing services for more than 27 commercial products. The company’s capabilities include innovative platforms, development and manufacturing capabilities for cell therapies and viral vectors, and extensive testing services.  With more than 25 years of cell therapy CDMO experience and over 40 years of experience in biosafety testing and product characterization, the new company will support the next wave of commercial cell therapies.

“CDMOs supporting the cell therapy industry have struggled to evolve from a small-scale cottage industry to deliver cost effective manufacturing at scale,” said Iain Baird, chairman of Minaris Advanced Therapies. “Our mission is to solve the development and manufacturing challenges preventing these promising therapies from successful worldwide commercialization.”

The team includes more than 1,400 industry professionals with deep scientific and regulatory expertise. The company’s testing business unit provides unrivalled expertise in analytical method development and GMP-grade biosafety and product characterization testing services for both in-house and external programs.

“Minaris Advanced Therapies is designed to help the industry treat more patients by providing the experience, global footprint, and platforms to accelerate timelines and enable commercialization,” said Eytan Abraham, Ph.D., chief commercial and technology officer.  “Many of the technologies needed to reduce cost of goods sold and improve turnaround time already exist, we will drive their adoption and implementation at scale.”

Built for speed, scale and science

Minaris Advanced Therapies brings together:

• More than 1,400 employees specializing in process and analytical development, manufacturing, quality control, quality assurance and regulatory compliance
• Facilities at six sites on three continents, totaling more than 730,000 square feet of infrastructure
• 42 state-of-the-art clean rooms for commercial use in Philadelphia, Allendale, NJ, Munich, and Yokohama, Japan
• Track record of more than 7,500 GMP batches released, with current manufacturing of two commercial products and testing of more than 27
• More than 20 successful inspections by global health agencies, including the FDA, EMA, TGA, PMDA, MFDS and USDA
• Over 40 years of biosafety and product characterization testing experience, with 1,700 assays developed, and 10,000 samples received annually
• 22 patents in discovery services, including key intellectual property for the TESSA® platform for scalable AAV and XOFLX^TM packaging and producer cell lines for lentiviral vector production

About Minaris Advanced Therapies

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 730,000 square feet of infrastructure across the United States, Europe and Asia. We have manufactured and released over 7,500 GMP batches and our global network supports therapy developers through early-stage development, clinical trials and commercial manufacturing. By combining scientific expertise with best-in-class manufacturing and testing services, we help bring safe, effective therapies to patients faster and more efficiently. Visit minaris.com to learn more or download the new company presentation here.

Philadelphia, U.S. and Oxford, U.K. sites and capabilities spun out of WuXi AppTec

We are excited to share that Altaris completed its acquisition of Advanced Therapies U.S. and OXGENE (together “Advanced Therapies”) on 7 March 2025. Advanced Therapies is now fully owned by Altaris and headquartered in the United States.

Altaris is an investment firm headquartered in New York with an exclusive focus on acquiring and building companies in the healthcare industry. With a 20+ year track record as an owner of healthcare companies, including 11 medical product contract development and manufacturing organizations (CDMOs), Altaris is well-positioned to support Advanced Therapies over its next phase of growth.

This transaction builds on Altaris’ strategic initiative for the cell therapy market, which is focused on delivering life-changing therapies to patients at scale. As part of this strategy, Altaris acquired Minaris Regenerative Medicine (“Minaris”) from Resonac Holdings Corporation in January of this year. Minaris is a cell therapy CDMO with commercially approved manufacturing facilities in the United States, Germany and Japan.

Altaris intends to combine Advanced Therapies and Minaris into a single company, Minaris Advanced Therapies. The combined company’s extensive track record, breadth of capabilities and global manufacturing footprint uniquely position it to deliver accelerated development timelines, reduced manufacturing costs, and greater patient access to life-saving treatments. Altaris expects to complete the operational combination of Minaris and Advanced Therapies in the first half of 2025. 

We look forward to introducing the industry to the new Minaris Advanced Therapies which will be a scaled and meaningful contributor to the future of cell therapies.  Stay tuned for more updates!  Questions?  Contact us.